as of 10-30-2026 3:35pm EST
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
| Founded: | 1856 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 12.3B | IPO Year: | 2002 |
| Target Price: | $32.32 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $26.30 - $37.09 | Next Earning Date: | 08-04-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4.85% | Revenue Growth (next year): | 5.25% |
| P/E Ratio: | 64.97 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +7.28% |
See how SNN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SNN Smith & Nephew SNATS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.